Concepedia

Natalie Cureton

NC

6

Publications

229

Citations

6

H-Index

2017

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

Natalie Cureton is an author at AstraZeneca (United Kingdom) specializing in molecular pharmacology, drug discovery, and tumor biology.

ORCID

Top concepts

Publications per year

2017–2024

6

Publications

6

Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy

Natalie Cureton, I. P. Korotkova, Bernadette Baker et al. · Theranostics · 2017 · 97 citations · Full text

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana R�os et al. · Cancer Research · 2023 · 54 citations · Full text

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

Shanade Dunn, Cath Eberlein, Jason Yu et al. · Oncogene · 2022 · 30 citations · Full text

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

Thomas G. Hayhow, Beth Williamson, Mandy Lawson et al. · Communications Biology · 2024 · 19 citations · Full text

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists

James S. Scott, Darren Stead, Bernard Barlaam et al. · Journal of Medicinal Chemistry · 2023 · 16 citations

Rows per page

1–5 of 6